ESTRACYT

Estracyt Adverse Events Reported to the FDA Over Time

How are Estracyt adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Estracyt, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Estracyt is flagged as the suspect drug causing the adverse event.

Most Common Estracyt Adverse Events Reported to the FDA

What are the most common Estracyt adverse events reported to the FDA?

Decreased Appetite	33 (2.23%)
Malaise	31 (2.1%)
Anaemia	30 (2.03%)
Interstitial Lung Disease	29 (1.96%)
Nausea	29 (1.96%)
Dyspnoea	24 (1.62%)
Vomiting	23 (1.56%)
Pulmonary Embolism	19 (1.28%)
Asthenia	18 (1.22%)
Oedema Peripheral	18 (1.22%)
Renal Failure Acute	18 (1.22%)
	Show More
Cardiac Failure Congestive	17 (1.15%)
Cerebral Infarction	17 (1.15%)
Diarrhoea	16 (1.08%)
Hepatic Function Abnormal	16 (1.08%)
Pleural Effusion	16 (1.08%)
Thrombocytopenia	16 (1.08%)
Nicotinic Acid Deficiency	15 (1.01%)
Neutropenia	14 (.95%)
Pyrexia	14 (.95%)
Cardiac Failure	12 (.81%)
Dysgeusia	12 (.81%)
Haemoglobin Decreased	12 (.81%)
Headache	12 (.81%)
Fatigue	11 (.74%)
Prostatic Specific Antigen Increase...	11 (.74%)
White Blood Cell Count Increased	11 (.74%)
Aspartate Aminotransferase Increase...	10 (.68%)
Deep Vein Thrombosis	10 (.68%)
Feeling Abnormal	10 (.68%)
Renal Impairment	10 (.68%)
Weight Decreased	10 (.68%)
White Blood Cell Count Decreased	10 (.68%)
Alanine Aminotransferase Increased	9 (.61%)
Angioedema	9 (.61%)
Cholelithiasis	9 (.61%)
Desmoid Tumour	9 (.61%)
Oedema	9 (.61%)
Blood Alkaline Phosphatase Increase...	8 (.54%)
Cough	8 (.54%)
Death	8 (.54%)
Drug Interaction	8 (.54%)
Myocardial Infarction	8 (.54%)
Pharyngeal Oedema	8 (.54%)
Pneumonia	8 (.54%)
Tongue Neoplasm Malignant Stage Uns...	8 (.54%)
Tongue Oedema	8 (.54%)
Anorexia	7 (.47%)
Disseminated Intravascular Coagulat...	7 (.47%)
Gastrointestinal Disorder	7 (.47%)
General Physical Health Deteriorati...	7 (.47%)
Hypertension	7 (.47%)
Liver Disorder	7 (.47%)
Neoplasm Malignant	7 (.47%)
Platelet Count Decreased	7 (.47%)
Haematocrit Decreased	6 (.41%)
Hypophagia	6 (.41%)
Jaundice	6 (.41%)
Laryngeal Oedema	6 (.41%)
Leukopenia	6 (.41%)
Metastases To Bone	6 (.41%)
Obesity	6 (.41%)
Pain	6 (.41%)
Arthralgia	5 (.34%)
Blood Glucose Increased	5 (.34%)
Colitis	5 (.34%)
Coma	5 (.34%)
Confusional State	5 (.34%)
Dehydration	5 (.34%)
Disease Progression	5 (.34%)
Dizziness	5 (.34%)
Dyspnoea Exertional	5 (.34%)
Fibrin D Dimer Increased	5 (.34%)
Gait Disturbance	5 (.34%)
Hypotension	5 (.34%)
Multi-organ Failure	5 (.34%)
Prostate Cancer	5 (.34%)
Sudden Death	5 (.34%)
Urinary Tract Infection	5 (.34%)
Asphyxia	4 (.27%)
Blood Creatinine Increased	4 (.27%)
Blood Lactate Dehydrogenase Increas...	4 (.27%)
Blood Pressure Decreased	4 (.27%)
Breast Pain	4 (.27%)
C-reactive Protein Increased	4 (.27%)
Coagulation Time Prolonged	4 (.27%)
Condition Aggravated	4 (.27%)
Constipation	4 (.27%)
Drug Toxicity	4 (.27%)
Dyslalia	4 (.27%)
Fall	4 (.27%)
Febrile Neutropenia	4 (.27%)
Gastrointestinal Necrosis	4 (.27%)
Haematuria	4 (.27%)
Hepatitis Toxic	4 (.27%)
Hypoproteinaemia	4 (.27%)
Liver Function Test Abnormal	4 (.27%)
Malignant Neoplasm Progression	4 (.27%)
Micturition Frequency Decreased	4 (.27%)
Myelodysplastic Syndrome	4 (.27%)
Neutropenic Sepsis	4 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Estracyt, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Estracyt is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Estracyt

What are the most common Estracyt adverse events reported to the FDA?

Hematology Investigations	77 (5.21%)
Gastrointestinal Signs	62 (4.19%)
Neurological	55 (3.72%)
Appetite And General Nutritional	53 (3.58%)
Respiratory	53 (3.58%)
Hepatic And Hepatobiliary	41 (2.77%)
Lower Respiratory Tract Disorders	40 (2.7%)
Infections - Pathogen Unspecified	36 (2.43%)
Renal Disorders	34 (2.3%)
Anemias Nonhemolytic And Marrow Dep...	32 (2.16%)
Heart Failures	31 (2.1%)
	Show More
Hepatobiliary	31 (2.1%)
Epidermal And Dermal Conditions	28 (1.89%)
White Blood Cell	28 (1.89%)
Pulmonary Vascular	25 (1.69%)
Central Nervous System Vascular	23 (1.56%)
Gastrointestinal Motility And Defec...	20 (1.35%)
Upper Respiratory Tract Disorders	20 (1.35%)
Urinary Tract Signs	19 (1.28%)
Embolism And Thrombosis	17 (1.15%)
Platelet	16 (1.08%)
Pleural	16 (1.08%)
Body Temperature Conditions	15 (1.01%)
Coronary Artery	15 (1.01%)
Electrolyte And Fluid Balance Condi...	15 (1.01%)
Metastases	15 (1.01%)
Therapeutic And Nontherapeutic Effe...	15 (1.01%)
Vitamin Related	15 (1.01%)
Cardiac And Vascular Investigations	14 (.95%)
Physical Examination Topics	14 (.95%)
Cardiac Arrhythmias	13 (.88%)
Fatal Outcomes	13 (.88%)
Miscellaneous And Site Unspecified ...	13 (.88%)
Enzyme	12 (.81%)
Headaches	12 (.81%)
Immunology And Allergy	11 (.74%)
Gastrointestinal Inflammatory Condi...	10 (.68%)
Oral Soft Tissue Conditions	10 (.68%)
Tongue Conditions	10 (.68%)
Angiedema And Urticaria	9 (.61%)
Bacterial Infectious	9 (.61%)
Bone Disorders	9 (.61%)
Gallbladder	9 (.61%)
Gastrointestinal Conditions	9 (.61%)
Renal And Urinary Tract Investigati...	9 (.61%)
Soft Tissue Neoplasms Benign	9 (.61%)
Gastrointestinal Neoplasms Malignan...	8 (.54%)
Gastrointestinal Ulceration And Per...	8 (.54%)
Injuries	8 (.54%)
Leukemias	8 (.54%)
Metabolic, Nutritional And Blood Ga...	8 (.54%)
Ocular Infections, Irritations And ...	8 (.54%)
Coagulopathies And Bleeding Diathes...	7 (.47%)
Decreased And Nonspecific Blood Pre...	7 (.47%)
Movement Disorders	7 (.47%)
Reproductive Neoplasms Male Maligna...	7 (.47%)
Skin Appendage Conditions	7 (.47%)
Vascular Hypertensive	7 (.47%)
Water, Electrolyte And Mineral	7 (.47%)
Deliria	6 (.41%)
Gastrointestinal Vascular Condition...	6 (.41%)
Peripheral Neuropathies	6 (.41%)
Protein And Amino Acid Metabolism	6 (.41%)
Bone, Calcium, Magnesium And Phosph...	5 (.34%)
Breast	5 (.34%)
Cardiac Disorder Signs	5 (.34%)
Gastrointestinal Hemorrhages	5 (.34%)
Joint	5 (.34%)
Prostatic Disorders	5 (.34%)
Protein And Chemistry Analyses	5 (.34%)
Vascular Hemorrhagic	5 (.34%)
Administration Site Reactions	4 (.27%)
Bronchial Disorders	4 (.27%)
Chemical Injury And Poisoning	4 (.27%)
Gastrointestinal Stenosis And Obstr...	4 (.27%)
Musculoskeletal And Connective Tiss...	4 (.27%)
Vascular	4 (.27%)
Anxiety Disorders	3 (.2%)
Depressed Mood Disorders	3 (.2%)
Hematological And Lymphoid Tissue T...	3 (.2%)
Inner Ear And Viiith Cranial Nerve	3 (.2%)
Lifestyle Issues	3 (.2%)
Medication Errors	3 (.2%)
Microbiology And Serology	3 (.2%)
Myocardial	3 (.2%)
Penile And Scrotal Disorders	3 (.2%)
Skin And Subcutaneous Tissue	3 (.2%)
Sleep Disorders	3 (.2%)
Testicular And Epididymal	3 (.2%)
Therapeutic Procedures And Supporti...	3 (.2%)
Ureteric	3 (.2%)
Urolithiases	3 (.2%)
Vision	3 (.2%)
Adrenal Gland	2 (.14%)
Bladder And Bladder Neck Disorders	2 (.14%)
Bone And Joint Injuries	2 (.14%)
Hematological	2 (.14%)
Hepatobiliary Neoplasms Malignant A...	2 (.14%)
Injuries By Physical Agents	2 (.14%)
Mental Impairment	2 (.14%)
Metabolism	2 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Estracyt, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Estracyt is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.